196 related articles for article (PubMed ID: 11384742)
1. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.
Johnson MR; Diasio RB
Adv Enzyme Regul; 2001; 41():151-7. PubMed ID: 11384742
[No Abstract] [Full Text] [Related]
2. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
[TBL] [Abstract][Full Text] [Related]
3. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
Gardiner SJ; Begg EJ; Robinson BA
Adverse Drug React Toxicol Rev; 2002; 21(1-2):1-16. PubMed ID: 12140902
[TBL] [Abstract][Full Text] [Related]
4. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
[TBL] [Abstract][Full Text] [Related]
6. When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring.
Tron C; Lemaitre F; Boisteau E; Sourd SL; Lièvre A
Dig Liver Dis; 2021 Feb; 53(2):258-260. PubMed ID: 33229275
[No Abstract] [Full Text] [Related]
7. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
Wei X; McLeod HL; McMurrough J; Gonzalez FJ; Fernandez-Salguero P
J Clin Invest; 1996 Aug; 98(3):610-5. PubMed ID: 8698850
[TBL] [Abstract][Full Text] [Related]
8. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
Mattison LK; Soong R; Diasio RB
Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
[TBL] [Abstract][Full Text] [Related]
9. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.
Lu Z; Zhang R; Carpenter JT; Diasio RB
Clin Cancer Res; 1998 Feb; 4(2):325-9. PubMed ID: 9516918
[TBL] [Abstract][Full Text] [Related]
10. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
11. [Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil].
Katona C; Rosta A; Tóth K; Fónyad G; Jeney A; Pandi E; Kralovánszky J
Orv Hetil; 1997 Jul; 138(29):1843-7. PubMed ID: 9280881
[TBL] [Abstract][Full Text] [Related]
12. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
Milano G; McLeod HL
Eur J Cancer; 2000 Jan; 36(1):37-42. PubMed ID: 10741292
[TBL] [Abstract][Full Text] [Related]
13. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
14. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
Milano G; Etienne MC
Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
[TBL] [Abstract][Full Text] [Related]
15. Known variant DPYD alleles do not explain DPD deficiency in cancer patients.
Collie-Duguid ES; Etienne MC; Milano G; McLeod HL
Pharmacogenetics; 2000 Apr; 10(3):217-23. PubMed ID: 10803677
[TBL] [Abstract][Full Text] [Related]
16. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
[TBL] [Abstract][Full Text] [Related]
17. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice.
Latchman J; Guastella A; Tofthagen C
Clin J Oncol Nurs; 2014 Oct; 18(5):581-5. PubMed ID: 25253112
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
Ezzeldin H; Diasio R
Clin Colorectal Cancer; 2004 Sep; 4(3):181-9. PubMed ID: 15377401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]